Frontline Plc FRO 深 滬
已收盤 05-22 16:00:00 美东时间
37.12
-1.320
-3.43%
華盛通- 最 高38.05
- 今 開37.97
- 成交量 435.02万股
- 最 低 36.47
- 昨 收 38.44
- 總市值 82.64亿
- 52周最高 39.74
- 市盈率 靜 21.80
- 換手率 1.95%
- 52周最低 14.665
- 委 比 35.83%
- 總股本 2.23亿
- 歷史最高 41.67
- 量 比 1.61
- 振 幅 4.11%
- 歷史最低 -4.84
- 每 手 1
- 風險率 7.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Frontline declares $1.55 dividend
Frontline (FRO) declares $1.55/share quarterly dividend. Forward yield 16.7% Payable June 23; for shareholders of record June 12; ex-div June 12. See FRO Dividend Scorecard, Yield Chart, & Dividend Gr...
05-23 14:36
Frontline Earnings Call Signals Powerful Tanker Upswing
Frontline (($FRO)) has held its Q1 earnings call. Read on for the main highligh...
05-23 08:12
Frontline第一季度利润创20年新高，每股1.55派发美元股息
Frontline plc于5月22日公布2026年第一季度业绩，因中东贸易路线中断大幅推高油轮运价，公司录得自2004年第四季度以来最强劲的季度调整后利润...
05-23 03:47
Frontline CEO Says Hormuz Chaos Supercharged Tanker Profits
Strong tanker rates push Frontline (FRO) Q1 revenue to $714.2M, beating Wall Street expectations. Full report inside.
05-23 00:12
Frontline outlines $1.5B cash generation potential as Q2 VLCC bookings reach $181,700/day
Earnings Call Insights: Frontline plc (FRO) Q1 2026 Management View CEO Lars Barstad framed operating conditions around the Middle East disruption, saying, "I did not imagine us in a situation for thi...
05-22 23:41
Frontline Q1 Adj. EPS $1.55 Beats $1.45 Estimate, Sales $714.242M Beat $570.806M Estimate
Frontline (NYSE:FRO) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.45 by 6.9 percent. This is a 761.11 percent increase over earnings of $0.18 per share from the same
05-22 17:02
Here are the major earnings before the open Friday
Major earnings expected before the bell on Friday include: Global Ship Lease (GSL) Frontline plc (FRO) Booz Allen Hamilton Holding Corporation (BAH) Imperial Petroleum (IMPP) Other earnings slated for...
05-22 06:00
Kura Oncology Reports First Quarter 2026 Financial Results
Kura Oncology reported first-quarter 2026 financial results, with $5.8 million in net product revenue for KOMZIFTI™ (ziftomenib) in its first full quarter of commercialization. The company achieved strong early momentum with 85 new patient starts, 157 total prescriptions, and over 93% payer coverage. Clinical advancements include ongoing trials across AML treatment settings, with multiple data readouts expected in 2026. Kura also highlighted its ...
05-12 20:02
Zebra FY26 Q1 net income slips 0.7% to $135 million; net sales rise 14.3% to $1.5 billion
Zebra FY26 Q1 net income slips 0.7% to $135 million; net sales rise 14.3% to $1.5 billion Zebra Technologies posted first-quarter net sales of USD 1.5 billion, up 14.3% year over year, while net income edged down 0.7% to USD 135 million. Diluted EPS rose 3.8% to USD 2.72, while gross margin widened
05-12 18:31
